Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )

AIMS: To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin–angiotensin–aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF). METHODS AND RESULTS: A total of 1642 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, Javed, Anker, Stefan D, Lund, Lars H, Coats, Andrew J S, Filippatos, Gerasimos, Siddiqi, Tariq Jamal, Friede, Tim, Fabien, Vincent, Kosiborod, Mikhail, Metra, Marco, Piña, Ileana L, Pinto, Fausto, Rossignol, Patrick, van der Meer, Peter, Bahit, Cecilia, Belohlavek, Jan, Böhm, Michael, Brugts, Jasper J, Cleland, John G F, Ezekowitz, Justin, Bayes-Genis, Antoni, Gotsman, Israel, Goudev, Assen, Khintibidze, Irakli, Lindenfeld, Joann, Mentz, Robert J, Merkely, Bela, Montes, Eliodoro Castro, Mullens, Wilfried, Nicolau, Jose C, Parkhomenko, Aleksandr, Ponikowski, Piotr, Seferovic, Petar M, Senni, Michele, Shlyakhto, Evgeny, Cohen-Solal, Alain, Szecsödy, Peter, Jensen, Klaus, Dorigotti, Fabio, Weir, Matthew R, Pitt, Bertram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Fast track
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622299/
https://www.ncbi.nlm.nih.gov/pubmed/35900838
http://dx.doi.org/10.1093/eurheartj/ehac401

Ejemplares similares

Ejemplares similares